Health Condition 1: C692- Malignant neoplasm of retina
Conditions
Interventions
Intervention1: CHEMOTHERAPY, SURGERY, RADIOTHERAPY, AUTOLOGOUS STEM CELL TRANSPLANTATION: CHEMOTHERAPY, SURGERY, RADIOTHERAPY, AUTOLOGOUS STEM CELL TRANSPLANTATION
Control Intervention1: NIL: NIL
Sponsors
DR RAJENDRA PRASAD CENTRE FOR OPHTHALMIC SCIENCES AIIMS NEW DELHI
Eligibility
Inclusion criteria
Inclusion criteria: CASES DIAGNOSED WITH 1.IRSS STAGE 2: PATIENTS WHO UNDERWENT ENUCLEATION BUT HAVE MICROSCOPIC RESIDUAL DISEASE (THE PATIENT WITH INVOLVEMENT OF THE OPTIC NERVE TO THE TRANSECTION LINE AND THOSE WITH MICROSCOPIC TRANS-SCLERAL INVASION ON HISTOPATHOLOGY 2. IRSS STAGE 3: PATIENTS WITH REGIONAL EXTENSION 3A: PATIENTS WITH OVERT ORBITAL DISEASE 3B: PATIENT WITH PREAURICULAR OR CERVICAL LYMPH NODE EXTENSION 3. IRSS STAGE 4: PATIENTS WITH HAEMATOGENOUS METASTASES NOT INVOLVING THE CNS (STAGE 4A) AND THOSE WITH CNS DISEASE (STAGE 4B)
Exclusion criteria
Exclusion criteria: IRSS STAGE 0 AND 1 RETINOBLASTOMA PATIENTS NOT WILLING FOR TREATMENT PATIENTS NOT WILLING FOR FOLLOW-UP
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To study the treatment outcomes of extraocular retinoblastoma following multimodal therapy. 2. To study the adverse effects of treatment Timepoint: Outcome will be assessed at baseline, 3 months , 6 months, 12 months, 18 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the risk factors associated with extraocular retinoblastomaTimepoint: 1.5YEARS | — |
Countries
India
Contacts
Public ContactPRITA KARMACHARYA
ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI
Outcome results
None listed